Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

UK pharma continues to approach social media cautiously

Novartis UK becomes the latest in a trickle of firms to join Twitter

Pharma TwitterNovartis UK has joined Twitter, becoming the latest pharma firm to do so in the country, where a cautious approach continues to be the order of the day.

Outlining its Twitter guidelines, Novartis plans a 48-hour turnaround for responding to direct messages and asks users not to turn to the network to report adverse events.

The UK industry has long been told that there's nothing to stop it using social media as long as it remains compliant with ABPI's Code of Practice, but few have taken the plunge.

Among those that have are the likes of GSK and AZ, whose UK-headquartered operations make Twitter use a communications must.

Meanwhile, affiliates that have made longstanding use of the platform include Janssen UK and Bayer UK (both of which joined in January 2010), and Boehringer Ingelheim UK.

However, a number of UK companies are planning to ramp up their use of social media in the coming months, among them Lilly UK and Pfizer UK. The latter firm has said it wants to make “a step-change in Pfizer's presence across existing and emerging social media networks”.

29th November 2016

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics